Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01925417

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea — PUNCH CD  

Recurrent Clostridium Difficile Infection Clinical Trial

Official title:
A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

Clinical Trial Summary

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.

Clinical Trial Description

This is the first study of a microbiota suspension derived from intestinal microbes. The primary assessments for this open label, multi-center study are (i) occurrence of product-related adverse events and (ii) resolution of CDAD at 56 days after administration of RBX2660. Subjects will also be assessed for time to CDAD recurrence, quality of life changes, and number of hospitalizations and length of stay for recurrent CDAD. Study visits will be at 7, 30, and 60 days after RBX2660 administration with additional follow-up at 3 and 6 months post treatment. Patients who have had at least two recurrences of CDAD after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDAD resulting in hospitalization may be eligible for the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01925417
Study type Interventional
Source Rebiotix Inc.
Contact
Status Completed
Phase Phase 2
Start date August 2013
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT05201079 - Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin Phase 3
Terminated NCT01226992 - Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin Phase 2/Phase 3
Not yet recruiting NCT04960306 - Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05826418 - Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation N/A
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Suspended NCT01202630 - BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection Phase 3
Terminated NCT03973697 - Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection Phase 2
Completed NCT03353506 - Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection Phase 2
Available NCT03786900 - Fecal Microbiota Transplantation (FMT): PRIM-DJ2727